High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Circulation

• Publication date

  2004-09-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.0000141728.23033.B5PMID 15353498
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin

  2005cited by this paper
• Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

  2004cited by this paper
• Thematic review series: The Pathogenesis of Atherosclerosis Published, JLR Papers in Press, April 1, 2004. DOI 10.1194/jlr.R400001-JLR200 The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL

  2004cited by this paper
• Comparison of intensive and moderate lipid lowering with statins after acute coronary symptoms

  2004cited by this paper
• Percutaneous Coronary Intervention Results in Acute Increases in Oxidized Phospholipids and Lipoprotein(a): Short-Term and Long-Term Immunologic Responses to Oxidized Low-Density Lipoprotein

  2004cited by this paper
• Oral D-4F Causes Formation of Pre-βHigh-Density Lipoprotein and Improves High-Density Lipoprotein–Mediated Cholesterol Efflux and Reverse Cholesterol Transport From Macrophages in Apolipoprotein E–Null Mice

  2004cited by this paper
• Changes in Dietary Fat Intake Alter Plasma Levels of Oxidized Low-Density Lipoprotein and Lipoprotein(a)

  2004cited by this paper
• Lysine-Phosphatidylcholine Adducts in Kringle V Impart Unique Immunological and Potential Pro-inflammatory Properties to Human Apolipoprotein(a)*

  2003cited by this paper
• High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study

  2003cited by this paper
• Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.

  2003cited by this paper
• Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes.

  2003cited by this paper
• A Single Protease, Apg4B, Is Specific for the Autophagy-related Ubiquitin-like Proteins GATE-16, MAP1-LC3, GABARAP, and Apg8L*

  2003cited by this paper
• Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL

  2003cited by this paper
• Statins and Oxidative Stress During Atherogenesis

  2003cited by this paper
• Immunoglobulin M Type of Autoantibodies to Oxidized Low-Density Lipoprotein Has an Inverse Relation to Carotid Artery Atherosclerosis

  2003cited by this paper
• Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects.

  2002cited by this paper
• Single LDL apheresis improves serum remnant-like particle-cholesterol, C-reactive protein, and malondialdehyde-modified-low-density lipoprotein concentrations in Japanese hypercholesterolemic subjects.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary

  2002cited by this paper
• Oxidized LDL in Carotid Plaques and Plasma Associates With Plaque Instability

  2002cited by this paper
• Lipid Lowering Reduces Oxidative Stress and Endothelial Cell Activation in Rabbit Atheroma

  2002cited by this paper
• Lipoprotein(a): still an enigma?

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• Low-Density Lipoprotein Level Reduction by the 3-Hydroxy-3-Methylglutaryl Coenzyme-A Inhibitor Simvastatin Is Accompanied by a Related Reduction of F2-Isoprostane Formation in Hypercholesterolemic Subjects: No Further Effect of Vitamin E

  2002cited by this paper
• Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques: Implications for Plaque Stabilization

  2001cited by this paper
• Antibodies to Oxidized LDL in Relation to Intima-Media Thickness in Carotid and Femoral Arteries in 58-Year-Old Subjectively Clinically Healthy Men

  2001cited by this paper
• Elevated Levels of Oxidized Low Density Lipoprotein Show a Positive Relationship With the Severity of Acute Coronary Syndromes

  2001cited by this paper
• Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein.

  2001cited by this paper
• Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study.

  2001cited by this paper
• Early statin treatment following acute myocardial infarction and 1-year survival.

  2001cited by this paper
• Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors.

  2001cited by this paper
• Evidence for a role of phospholipid oxidation products in atherogenesis.

  2001cited by this paper
• Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

  2001cited by this paper
• In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression.

  2000cited by this paper
• Autoantibodies to OxLDL are decreased in individuals with borderline hypertension.

  1999cited by this paper
• Malondialdehyde-modified LDL as a marker of acute coronary syndromes.

  1999cited by this paper
• Lipoprotein(a): intrigues and insights.

  1999cited by this paper
• Improvement of coronary vasodilatation capacity through single LDL apheresis.

  1998cited by this paper
• A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.

  1998cited by this paper
• Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization.

  1998cited by this paper
• Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation.

  1998cited by this paper
• Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans.

  1997cited by this paper
• A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia

  1997cited by this paper
• A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.

  1997cited by this paper
• Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia.

  1996cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease.

  1994cited by this paper

• Analytical validation of monoclonal antibody-based ELISA methods for OxPL-apoB and OxPL-apo(a)

  2026cites this paper
• Molecular and Immunomodulatory Mechanisms of Statins in Inflammation and Cancer Therapeutics with Emphasis on the NF-κB, NLRP3 Inflammasome, and Cytokine Regulatory Axes

  2025cites this paper
• Statin effect on arrhythmogenic cardiomyopathy disease progression (SEARCH): Randomized clinical study protocol

  2025cites this paper
• Effect of lipid-lowering medications on oxidized phospholipids in individuals with elevated LIPOPROTEIN(a)

  2025influential citation
• Lipoprotein(a) Lipidome: Responses to Reduced Dietary Saturated Fat Intake in Two Randomized Controlled Feeding Trials

  2025cites this paper
• Statins—Their Effect on Lipoprotein(a) Levels

  2025cites this paper
• Oxidized Phospholipids on ApoB-100, Platelet Activation and Reactivity, and Long-Term Cardiovascular Outcomes

  2025cites this paper
• Lipoprotein(a) as a cardiovascular risk factor among patients with and without diabetes Mellitus: the Mass General Brigham Lp(a) Registry

  2024cites this paper
• Variation in lipoprotein(a) response to potent lipid lowering: The role of apolipoprotein (a) isoform size.

  2024cites this paper
• A nonionic microemulsion co-loaded with atorvastatin and quercetin: Simultaneous spectroscopic analysis and payload release kinetics.

  2024cites this paper
• Diacylglycerols and Lysophosphatidic Acid, Enriched on Lipoprotein(a), Contribute to Monocyte Inflammation

  2024cites this paper
• Serum lipid peroxidation potential as a biomarker for risk-stratification of coronary artery disease in patients with type 2 diabetes mellitus.

  2024cites this paper
• Research Hotspots and Development Trends on Apolipoprotein B in the Field of Atherosclerosis: A Bibliometric Analysis

  2024cites this paper
• Correlation Between Elevated Lipoprotein(a) and Carotid Plaque in Asymptomatic Individuals

  2024cites this paper
• Plasma tissue-type plasminogen activator is associated with lipoprotein(a) and clinical outcomes in hospitalized patients with COVID-19

  2023cites this paper
• Lipoprotein(a): a genetically determined risk factor for Cardiovascular disease

  2023cites this paper
• Lipoprotein(a): cardiovascular risk and emerging therapies

  2023cites this paper
• Oxidized low-density lipoprotein associates with cardiovascular disease by a vicious cycle of atherosclerosis and inflammation: A systematic review and meta-analysis

  2023cites this paper
• Oxidized phospholipids in cardiovascular disease

  2023cites this paper
• High immunoglobulin-M levels to oxidation-specific epitopes are associated with lower risk of acute myocardial infarction

  2023cites this paper
• Lipoprotein(a), platelet function and cardiovascular disease

  2023cites this paper
• Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention

  2023cites this paper
• Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia

  2023cites this paper
• Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes.

  2023cites this paper
• Role of Lipoprotein(a) in Cardiovascular Disease: A Review of Clinical Practice

  2022cites this paper
• Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial.

  2022cites this paper
• Lipoprotein(a), a Lethal Player in Calcific Aortic Valve Disease

  2022influential citation
• Lipoprotein(a) and Atherosclerotic Cardiovascular Disease, the Impact of Available Lipid-Lowering Medications on Lp(a): An Update on New Therapies.

  2022cites this paper
• Oxidized phospholipids on apolipoprotein B-100 versus plasminogen and risk of coronary heart disease in the PROCARDIS study.

  2022cites this paper
• Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology.

  2022cites this paper
• The Effects of Statin Therapy on Oxidized LDL and Its Antibodies: A Systematic Review and Meta-Analysis

  2022cites this paper
• Serum cholesterol loading capacity on macrophages is regulated by seropositivity and C-reactive protein in rheumatoid arthritis patients.

  2022cites this paper
• Structure and Dynamics of Oxidized Lipoproteins In Vivo: Roles of High-Density Lipoprotein

  2021cites this paper
• Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis.

  2021cites this paper
• Oxidized LDL‐dependent pathway as new pathogenic trigger in arrhythmogenic cardiomyopathy

  2021cites this paper
• Oxidized phospholipids and lipoprotein(a): An update

  2021cites this paper
• Measuring the contribution of Lp(a) cholesterol towards LDL-C interpretation.

  2020cites this paper
• Long-term atorvastatin or the combination of atorvastatin and nicotinamide ameliorate insulin resistance and left ventricular diastolic dysfunction in a murine model of obesity.

  2020cites this paper
• Intravenous Statin Administration During Myocardial Infarction Compared With Oral Post-Infarct Administration.

  2020cites this paper
• Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis

  2020cites this paper
• Effect of bariatric surgery on plasma levels of oxidised phospholipids, biomarkers of oxidised LDL and lipoprotein(a).

  2020cites this paper
• Statin therapy increases lipoprotein(a) levels.

  2020cites this paper
• Effect of different types and dosages of statins on plasma lipoprotein(a) levels: A network meta-analysis.

  2020cites this paper
• Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis - Novel insights and future directions in diagnosis and therapy.

  2019cites this paper
• 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.

  2019cites this paper
• Molecular pathways involved in the cardioprotective effects of intravenous statin administration during ischemia

  2019cites this paper
• Oxidized lipids: not just another brick in the wall 1.

  2019cites this paper
• 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

  2019cites this paper
• Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease

  2019cites this paper
• Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype.

  2019cites this paper
• The Significance of Oxidized Low-Density Lipoprotein in Body Fluids as a Marker Related to Diseased Conditions.

  2019cites this paper
• Lp(a) and PCSK9 : From concept to clinical practice

  2019cites this paper
• Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.

  2018cites this paper
• The role of B cells in atherosclerosis

  2018cites this paper
• In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members.

  2018cites this paper
• Oxidized low-density lipoprotein predicts recurrent stroke in patients with minor stroke or TIA

  2018cites this paper
• A Meta-Analysis of the Effect of PCSK9-Monoclonal Antibodies on Circulating Lipoprotein (a) Levels

  2018cites this paper
• Long-term statin therapy could be efficacious in reducing the lipoprotein (a) levels in patients with coronary artery disease modified by some traditional risk factors.

  2017cites this paper
• Lipid Biomarkers for Risk Assessment in Acute Coronary Syndromes

  2017cites this paper
• LDL fatty acids composition as a risk biomarker of cardiovascular disease

  2017cites this paper
• Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events

  2017cites this paper
• Elevated Lp(a) and Abdominal Aortic Aneurysm

  2017cites this paper
• Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack.

  2017cites this paper
• Lipoprotein(a) Mass Levels Increase Significantly According to APOE Genotype: An Analysis of 431 239 Patients

  2017cites this paper
• 2015 Russell Ross Memorial Lecture in Vascular Biology: Protective Autoimmunity in Atherosclerosis

  2016cites this paper
• Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis

  2016cites this paper
• Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.

  2016cites this paper
• Pleiotropic effects of statins: new therapeutic targets in drug design

  2016cites this paper
• Ley Protective Autoimmunity in Atherosclerosis 431

  2016cites this paper
• Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a).

  2016cites this paper
• Novel immune assay for quantification of plasma protective capacity against oxidized phospholipids.

  2016cites this paper
• Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk

  2016cites this paper
• Simvastatin Efficiently Lowers Small LDL-IgG Immune Complex Levels: A Therapeutic Quality beyond the Lipid-Lowering Effect

  2016cites this paper
• Malondialdehyde Epitopes as Targets of Immunity and the Implications for Atherosclerosis.

  2016cites this paper
• Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction

  2016cites this paper
• Lipoprotein-Associated Oxidative Stress

  2016cites this paper
• Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis

  2016cites this paper
• Protective Role for B-1b B Cells and IgM in Obesity-Associated Inflammation, Glucose Intolerance, and Insulin Resistance

  2016cites this paper
• Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study1

  2016cites this paper
• A CTUALIZACIÓN Y F UTURO D EL Ó XIDO N ÍTRICO EN E L T RATAMIENTO D E L A E NFERMEDAD C ARDIOVASCULAR

  2016cites this paper
• Eicosapentaenoic Acid Inhibits Oxidation of ApoB-containing Lipoprotein Particles of Different Size In Vitro When Administered Alone or in Combination With Atorvastatin Active Metabolite Compared With Other Triglyceride-lowering Agents

  2016cites this paper
• Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial.

  2015cites this paper
• 8 – Atherosclerotic plaque

  2015cites this paper
• Clinical Use of Serum Biomarkers in the Prediction of Cardiovascular Risk

  2015cites this paper
• Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism.

  2015cites this paper
• ‘LDL-C’ = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering

  2015cites this paper
• Splenic extrafollicular reactions and BM plasma cells sustain IgM response associated with hypercholesterolemia

  2015cites this paper
• Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases

  2015cites this paper
• Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With Hypercholesterolemia: Results of 4 Phase III Trials

  2015cites this paper
• Interrelatedness between C-reactive protein and oxidized low-density lipoprotein

  2015cites this paper
• Role of Oxidized Phospholipids in Cardiovascular Disease

  2015cites this paper
• Atorvastatin helps preserve pancreatic β cell function in obese C57BL/6 J mice and the effect is related to increased pancreas proliferation and amelioration of endoplasmic-reticulum stress

  2014cites this paper
• Unique Antibody Responses to Malondialdehyde-Acetaldehyde (MAA)-Protein Adducts Predict Coronary Artery Disease

  2014cites this paper
• Latest developments in the treatment of lipoprotein (a)

  2014cites this paper
• Relationship Between Oxidized LDL, IgM, and IgG Autoantibodies to ox-LDL Levels With Recurrent Cardiovascular Events in Swedish Patients With Previous Myocardial Infarction

  2014cites this paper
• Misfolding of apoprotein B-100, LDL aggregation and 17-β -estradiol in atherogenesis.

  2014cites this paper
• Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.

  2014cites this paper
• Oxidised phospholipids as biomarkers in human disease.

  2014cites this paper
• New and Emerging Risk Factors for Coronary Heart Disease

  2014cites this paper
• Hyperlipidemia, tissue factor, coagulation, and simvastatin.

  2014cites this paper